CD19 UCAR-T cell therapy for severe autoimmune diseases
Part of Blood & lymphatic, Bones, joints & muscles, Eyes & vision, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study tests a new cell therapy called CD19 UCAR-T. It is being studied for people with certain severe autoimmune conditions that have not improved with regular treatments. The goal is to see if this therapy can help control the immune system and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 65 years old.
- You must have tried standard treatments (like steroids or immune-suppressing drugs) and they didn't work or stopped working.
- You cannot have had CAR-T therapy or other gene therapy before.
- You cannot have an active cancer (except cured cervical or skin cancer).
- Your organs (blood, liver, kidneys, heart, lungs) must be working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
This early-stage trial tests a new type of immune cell therapy (UCAR T cells) for autoimmune diseases that have not responded to usual treatments. The therapy targets specific markers on immune cells to potentially calm the overactive immune response causing your illness.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This trial is testing whether a type of immune cell therapy called CAR-T cells can help people with severe autoimmune diseases that have not improved with standard treatments. It may offer a new option for conditions like lupus, Sjogren's syndrome, or vasculitis when other therapies have failed.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.